CD8A and neoplasm: In this context, besides the incidental observation in one patient of a robust CMV pp65-specific CD8+ cell response after injection of autologous dendritic cells pulsed with an autologous tumor lysate (53), the use of CMV-specific T-cell therapy did not show a significant efficacy in a Phase I pivotal study for GBM patients (54), or in a larger cohort of patients treated at MD Anderson Cancer Center (55).